Phathom Pharmaceuticals, Inc. (PHAT)
- Previous Close
16.76 - Open
16.76 - Bid 18.09 x 700
- Ask 18.26 x 300
- Day's Range
16.53 - 18.90 - 52 Week Range
6.07 - 19.71 - Volume
1,376,521 - Avg. Volume
952,738 - Market Cap (intraday)
1.239B - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-5.18 - Earnings Date Nov 7, 2024 - Nov 11, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
22.57
Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
www.phathompharma.comRecent News: PHAT
View MorePerformance Overview: PHAT
Trailing total returns as of 10/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHAT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHAT
View MoreValuation Measures
Market Cap
1.15B
Enterprise Value
1.04B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
97.73
Price/Book (mrq)
--
Enterprise Value/Revenue
105.29
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-54.07%
Return on Equity (ttm)
--
Revenue (ttm)
9.92M
Net Income Avi to Common (ttm)
-297.11M
Diluted EPS (ttm)
-5.18
Balance Sheet and Cash Flow
Total Cash (mrq)
276.24M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-154.15M